Clinical Directors Meeting. The agenda included discussion of an HCV look-back, ethical concerns of a vCJD look-back exercise, the safety of Tuta packs when theyre reintroduced, apheresis strategy, SHOT inception, anti-HBc testing, hepatitis G (GBV-C), and Blood user groups.